Every time we speak, we're improvising. "Humans possess a remarkable ability to talk about almost anything, sometimes putting ...

Vast's first platform, Haven-1, is deliberately modest in scale but ambitious in both schedule and purpose. The station is designed as a roughly 15-ton autonomous outpost ...

Recently, JinkoSolar, a globally innovative photovoltaic enterprise, announced a strategic partnership with a renowned UK clean energy distributor, successfully securing a 56.89MW order for its ...

Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the ...

LONGi Green, Tongwei, JA Solar, TCL Zhonghuan and Aiko Solar are projecting a combined 2025 deficit of RMB28.9-32.8 billion ...

Sentiment among Europe’s solar buyers dropped to the lowest levels on record at the end of 2025, according to sun.store's ...

Until today, Haven-1 had a public launch date of mid-2026. However, as Haot explained in our interview, that launch date is ...

The proposed Coordinate-Aware Feature Excitation (CAFE) module and Position-Aware Upsampling (Pos-Up) module both adhere to ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

The IMCAS test team for the reconfigurable flexible on-orbit manufacturing platform. Credit: IMCAS HELSINKI — A Chinese institute recently completed ground tests on what it describes as a ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...